Valion Bio Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	1.3yrs

Recente managementupdates

Recent updates

Seeking Alpha • Oct 17

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Health technology company Tivic Health Systems (NASDAQ:TIVC) will acquire the Reliefband product line for nausea treatment and all related assets from Reliefband Technologies. The total consideration is of up to $33.5M, of which up to $1.5M can be paid in restricted common stock. TIVC will also acquire Reliefband's Reletex-branded prescription nausea treatments. Reliefband Technologies' patented products are backed by 40 peer-reviewed clinical studies. The transaction is expected to be consummated in Q4 or Q1 2023. The nausea treatment is a $2.4B market in the U.S. and $5.5B globally, according to QY Research. The market is said to be growing at 6.5% CAGR. TIVC shares were trading +14.57% pre-market. Source: Press Release

Analyse-artikel • Jul 15

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO

Valion Bio heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sheryle Bolton	Independent Chair of the Board	7.2yrs	US$117.00k	0.045% $ 1.0k
Christina Valauri	Independent Director	2.2yrs	US$66.60k	0.086% $ 1.9k
Michael Handley	Director	less than a year	US$735.03k	0.050% $ 1.1k
Thomas Jensen	Director	less than a year	geen gegevens	geen gegevens
Jared Malbin	Director	less than a year	geen gegevens	geen gegevens
J. Zikria	Independent Director	7.2yrs	US$59.10k	0% $ 0

1.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VBIO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/09/09 16:53
Aandelenkoers aan het einde van de dag	2026/09/09 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Valion Bio, Inc. wordt gevolgd door 1 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Hunter Diamond	Diamond Equity Research LLC

Valion Bio Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Valion Bio, Inc. Appoints Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs

Valion Bio, Inc., Annual General Meeting, May 28, 2026

Tivic Health Systems, Inc. Announces Blake Gurfein to Step Down as Chief Scientific Officer, Effective July 4, 2025

Tivic Health Systems, Inc., Annual General Meeting, Jun 30, 2025

Tivic Health Systems, Inc. Appoints Michael K. Handley as Chief Operating Officer and President of Tivic Biopharma

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Recent updates

Valion Bio, Inc. has withdrawn its Follow-on Equity Offering.

3i LP Delivers Letter to the Board of Valion Bio

Valion Bio Entolimod Dossier Accepted for Formal Review Under Ukraine Regulatory Equivalence Pathway

Valion Bio, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Valion Bio, Inc. to Report Q1, 2026 Results on May 14, 2026

Valion Bio, Inc. Receives First FDA -Precedent Study Protocol from NIAID for Entolimod

Valion Bio, Inc. Appoints Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs

Valion Bio, Inc., Annual General Meeting, May 28, 2026

New major risk - Share price stability

Tivic Health Systems to Present Entolimod TLR5 Agonist Lead Drug Candidate and Its Plans for an Oral Transmucosal Delivery Program for Entolimod

Tivic Health Systems, Inc. Receives Notification Of Non-Compliance With Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Share price stability

Third quarter 2025 earnings released: US$1.97 loss per share (vs US$3.93 loss in 3Q 2024)

New major risk - Financial position

Tivic Expands Intellectual Property Portfolio

Tivic Health Systems, Inc. to Report Q3, 2025 Results on Nov 14, 2025

Tivic Health Systems, Inc. has withdrawn its Follow-on Equity Offering in the amount of $20 million.

Tivic Health Systems, Inc. Completes Verification of Entolimod Cell Line, First Step in Establishing CGMP Manufacturing for BLA Filing

Tivic Health®? Systems, Inc. Receives Two Investigational New Drug Applications for Entolimod™? for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Second quarter 2025 earnings released: US$2.19 loss per share (vs US$5.37 loss in 2Q 2024)

Tivic Health Systems, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Tivic Health Systems, Inc. Announces Blake Gurfein to Step Down as Chief Scientific Officer, Effective July 4, 2025

Tivic Health Systems, Inc. Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc., Annual General Meeting, Jun 30, 2025

First quarter 2025 earnings released: US$2.52 loss per share (vs US$17.15 loss in 1Q 2024)

Tivic Health Systems, Inc. to Report Q1, 2025 Results on May 15, 2025

Tivic Health Systems Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Full year 2024 earnings released: US$19.68 loss per share (vs US$177 loss in FY 2023)

Tivic Health Systems, Inc. to Report Fiscal Year 2024 Results on Mar 21, 2025

Tivic Health Systems, Inc. and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System

Tivic Health Systems, Inc. Appoints Michael K. Handley as Chief Operating Officer and President of Tivic Biopharma

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Enrollment Complete in Tivic Health Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022